Form 8-K - Current report:
SEC Accession No. 0001628280-24-035603
Filing Date
2024-08-07
Accepted
2024-08-07 16:06:44
Documents
15
Period of Report
2024-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lyel-20240807.htm   iXBRL 8-K 27348
2 EX-99.1 lyel-20240807x8kexx991.htm EX-99.1 117828
6 a0000a.jpg GRAPHIC 6782
  Complete submission text file 0001628280-24-035603.txt   290655

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lyel-20240807.xsd EX-101.SCH 1895
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lyel-20240807_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lyel-20240807_pre.xml EX-101.PRE 12504
17 EXTRACTED XBRL INSTANCE DOCUMENT lyel-20240807_htm.xml XML 2725
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 241183649
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)